Department of Palliative Medicine, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Medicine Research Center, West China-PUMC C.C. Chen Institute of Health, West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
BMJ Support Palliat Care. 2024 Jan 8;13(e3):e664-e675. doi: 10.1136/spcare-2022-004085.
The utilisation of palliative sedation is often favoured by patients approaching end of life due to the presence of multiple difficult-to-manage symptoms during the terminal stage. This study aimed to identify the determinants of the use of palliative sedation.
To identify pertinent observational studies, a comprehensive search was performed in PubMed, Embase, Cochrane Library, and PsycINFO databases from their inception until March 2022. The methodological quality of the chosen prospective and retrospective cohort studies was assessed using the Newcastle Ottawa Scale, while the Agency for Healthcare Research and Quality was used to evaluate the methodological quality of the selected cross-sectional studies. For each potential determinant of interest, the collected data were synthesised and analysed, and in cases where data could not be combined, a narrative synthesis approach was adopted.
A total of 21 studies were analysed in this research, consisting of 4 prospective cohort studies, 7 retrospective cohort studies, and 10 cross-sectional studies. The findings indicated that several determinants were significantly associated with palliative sedation. These determinants included younger age, male gender, presence of tumours, dyspnoea, pain, delirium, making advanced medical end-of-life decisions, and dying in a hospital setting.
The findings of our review could help physicians identify patients who may need palliative sedation in advance and implement targeted interventions to reverse refractory symptoms, develop personalized palliative sedation programs, and ultimately improve the quality of palliative care services.
PROSPERO registration number CRD42022324720.
由于终末期存在多种难以控制的症状,接近生命终点的患者通常倾向于使用姑息性镇静。本研究旨在确定使用姑息性镇静的决定因素。
为了确定相关的观察性研究,我们在 PubMed、Embase、Cochrane 图书馆和 PsycINFO 数据库中进行了全面检索,检索时间从数据库建立到 2022 年 3 月。我们使用纽卡斯尔-渥太华量表评估了所选前瞻性和回顾性队列研究的方法学质量,而使用医疗保健研究与质量局评估了所选横断面研究的方法学质量。对于每个有意义的潜在决定因素,我们收集了相关数据并进行了综合分析,对于无法进行合并的数据,我们采用了叙述性综合方法。
本研究共分析了 21 项研究,其中包括 4 项前瞻性队列研究、7 项回顾性队列研究和 10 项横断面研究。结果表明,几个决定因素与姑息性镇静显著相关。这些决定因素包括年龄较小、男性、存在肿瘤、呼吸困难、疼痛、谵妄、做出高级医疗末期决策以及在医院环境中死亡。
我们的综述结果可以帮助医生提前识别可能需要姑息性镇静的患者,并实施有针对性的干预措施来逆转难治性症状,制定个性化的姑息性镇静计划,最终提高姑息治疗服务的质量。
PROSPERO 注册号 CRD42022324720。